Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

460 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Thalidomide in the management of multiple myeloma.
Barlogie B, Tricot G, Anaissie E. Barlogie B, et al. Semin Oncol. 2001 Dec;28(6):577-82. doi: 10.1016/s0093-7754(01)90027-2. Semin Oncol. 2001. PMID: 11740812 Review.
Prognosis and therapy in hairy cell leukemia.
Jansen J, den Ottolander GJ, Holdrinet RS, Tricot GJ, Hermans J. Jansen J, et al. Semin Oncol. 1984 Dec;11(4 Suppl 2):472-8. Semin Oncol. 1984. PMID: 6548834 No abstract available.
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Kelly KR, et al. Oncotarget. 2015 Dec 1;6(38):41275-89. doi: 10.18632/oncotarget.5753. Oncotarget. 2015. PMID: 26513296 Free PMC article.
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Franqui-Machin R, et al. Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800. Oncotarget. 2015. PMID: 26415231 Free PMC article. Review.
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.
Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Rosean TR, et al. Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x. Immunol Res. 2014. PMID: 24845460 Free PMC article. Review.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F. Shi J, et al. Blood. 2008 Feb 1;111(3):1309-17. doi: 10.1182/blood-2007-03-078535. Epub 2007 Oct 18. Blood. 2008. PMID: 17947507 Free PMC article.
What is the significance of molecular remission in multiple myeloma?
Tricot GJ. Tricot GJ. Clin Adv Hematol Oncol. 2007 Feb;5(2):91-5. Clin Adv Hematol Oncol. 2007. PMID: 17344796 Review.
New insights into role of microenvironment in multiple myeloma.
Tricot GJ. Tricot GJ. Int J Hematol. 2002 Aug;76 Suppl 1:334-6. doi: 10.1007/BF03165279. Int J Hematol. 2002. PMID: 12430876 Review.
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Barlogie B, et al. Br J Haematol. 2006 Oct;135(2):158-64. doi: 10.1111/j.1365-2141.2006.06271.x. Epub 2006 Aug 25. Br J Haematol. 2006. PMID: 16939489 Clinical Trial.
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Freytes CO, et al. Biol Blood Marrow Transplant. 2014 Dec;20(12):1949-57. doi: 10.1016/j.bbmt.2014.08.007. Epub 2014 Aug 16. Biol Blood Marrow Transplant. 2014. PMID: 25139216 Clinical Trial.
460 results
Jump to page
Feedback